留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

肠道微生态与炎症性肠病

何丽娟 张军东 安毛毛 姜远英

何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
引用本文: 何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
Citation: HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001

Gut microbiota and inflammatory bowel disease

  • 摘要: 炎症性肠病(inflammatory bowel disease,IBD)是一组病因未明、发病机制亦不明确的慢性肠道炎症性疾病,主要包括克罗恩病(Crohn's disease,CD)和溃疡性结肠炎(ulcerative colitis,UC)。近几十年的研究结果认为,其发病是环境、易感基因和肠道微生态3个要素相互作用的结果,且这些要素使IBD成为一种适合研究宿主与肠道微生物相互作用的高优先平台。最近,肠道菌群的图谱分析将IBD的发病机制与菌群各组成部分特征的改变相联系,进一步支持"肠道微生物和宿主相互作用的改变能形成IBD"这一观点。该文回顾性分析有关IBD患者体内微生物的研究文献,综述肠道微生态失衡对IBD的多方面影响,以动物模型和临床验证资料阐述不同的治疗方法改善肠道微生态变化的最新进展。
  • [1] Molodecky NA,Soon IS,Rabi DM,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology,2012, 142(1):46-54.
    [2] Dave M,Higgins PD,Middha S,et al. The human gut microbiome: current knowledge,challenges,and future directions[J].Transl Res,2012,160(4):246-257.
    [3] Huttenhower C,Kostic AD,Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome[J]. Immunity,2014,40(6):843-854.
    [4] Morgan XC,Segata N,Huttenhower C. Biodiversity and functional genomics in the human microbiome[J]. Trends Genet,2013,29(1):51-58.
    [5] Scaldaferri F,Gerardi V,Lopetuso LR,et al. Gut microbial flora,prebiotics,and probiotics in IBD: their current usage and utility[J]. Biomed Res Int,2013,2013:435268.
    [6] Hooper LV,Littman DR,Macpherson AJ. Interactions between the microbiota and the immune system[J].Science,2012,336(6086):1268-1273.
    [7] Boudeau J,Glasser AL,Masseret E,et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease[J].Infect Immun,1999,67(9):4499-4509.
    [8] Rolhion N,Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Inflamm Bowel Dis,2007,13(10):1277-1283.
    [9] Allen-Vercoe E,Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC?[J].Immunol Lett,2014,162(2PA):54-61.
    [10] Allen-Vercoe E,Strauss J,Chadee K. Fusobacterium nucleatum: an emerging gut pathogen?[J].Gut Microb,2011,2(5):294-298.
    [11] Ohkusa T,Okayasu I,Ogihara T,et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis[J]. Gut,2003,52(1):79-83.
    [12] Strauss J,Kaplan GG,Beck PL,et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host[J]. Inflamm Bowel Dis,2011,17(9):1971-1978.
    [13] Kostic AD,Chun E,Robertson L,et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microb,2013,14(2):207-215.
    [14] Kitajima S,Morimoto M,Sagara E,et al. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice[J]. Exp Anim,2001,50(5):387-395.
    [15] Kamada N,Chen G,Núez G. A complex microworld in the gut: harnessing pathogen-commensal relations[J]. Nat Med,2012,18(8):1190-1191.
    [16] Llopis M,Antolin M,Carol M,et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa[J]. Inflamm Bowel Dis,2009,15(2):275-283.
    [17] Varela E,Manichanh C,Gallart M,et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis[J]. Aliment Pharmacol Ther,2013,38(2):151-161.
    [18] Cadwell K,Patel KK,Maloney NS,et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine[J]. Cell,2010,141(7):1135-1145.
    [19] Trojanowska D,Zwolinska-Wcislo M,Tokarczyk M,et al. The role of Candida in inflammatory bowel disease. Estimation of transmission of C. albicans fungi in gastrointestinal tract based on genetic affinity between strains[J]. Med Sci Monit,2010,16(10):CR451-457.
    [20] Iliev ID,Funari VA,Taylor KD,et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis[J]. Science,2012,336(6086):1314-1317.
    [21] Morgan XC,Tickle TL,Sokol H,et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment[J]. Genome Biol,2012,13(9):R79.
    [22] Atarashi K,Tanoue T,Oshima K,et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota[J]. Nature,2013,500(7461):232-236.
    [23] Duncan SH,Hold GL,Barcenilla A,et al.Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces[J]. Int J Syst Evol Microbiol, 2002,52(Pt 5):1615-1620.
    [24] Khan KJ,Ullman TA,Ford A,et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and Meta-analysis[J]. Am J Gastroenterol,2011,106(4):661-673.
    [25] Lemon KP,Armitage GC,Relman DA,et al. Microbiota-targeted therapies: an ecological perspective[J]. Sci Transl Med,2012,4(137):137rv5.
    [26] Gevers D,Kugathasan S,Denson LA,et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microb,2014,15(3):382-392.
    [27] Wlodarska M,Willing B,Keeney KM,et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium induced colitis[J]. Infect Immun,2011,79(4):1536-1545.
    [28] Damman CJ,Miller SI,Surawicz CM,et al. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?[J].Am J Gastroenterol,2012,107(10):1452-1459.
    [29] Shahinas D,Silverman M,Sittler T,et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing[J]. MBio,2012,3(5):e00338-12.
    [30] Anderson JL,Edney RJ,Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease[J]. Aliment Pharmacol Ther,2012,36(6):503-516.
    [31] Morgan XC,Huttenhower C. Meta'omic analytic techniques for studying the intestinal microbiome[J]. Gastroenterology,2014,146(6):1437-1448.
  • [1] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202306040
    [2] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 1-6. doi: 10.12206/j.issn.2097-2024.202312054
  • 加载中
计量
  • 文章访问数:  3135
  • HTML全文浏览量:  234
  • PDF下载量:  581
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-11-13
  • 修回日期:  2015-03-17

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001

摘要: 炎症性肠病(inflammatory bowel disease,IBD)是一组病因未明、发病机制亦不明确的慢性肠道炎症性疾病,主要包括克罗恩病(Crohn's disease,CD)和溃疡性结肠炎(ulcerative colitis,UC)。近几十年的研究结果认为,其发病是环境、易感基因和肠道微生态3个要素相互作用的结果,且这些要素使IBD成为一种适合研究宿主与肠道微生物相互作用的高优先平台。最近,肠道菌群的图谱分析将IBD的发病机制与菌群各组成部分特征的改变相联系,进一步支持"肠道微生物和宿主相互作用的改变能形成IBD"这一观点。该文回顾性分析有关IBD患者体内微生物的研究文献,综述肠道微生态失衡对IBD的多方面影响,以动物模型和临床验证资料阐述不同的治疗方法改善肠道微生态变化的最新进展。

English Abstract

何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
引用本文: 何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
Citation: HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
参考文献 (31)

目录

    /

    返回文章
    返回